ZRANB1

Across TCGA pan-cancer cohorts, ZRANB1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZRANB1 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ZRANB1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZRANB1 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, OV, and HNSC are the cancer types where ZRANB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	1.000	0.259	.009	20	view →
OV	OS	Median	All	0.362	0.842	.005	18	view →
HNSC	OS	Median	All	0.176	0.685	.024	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	II,III,IV	0.256	0.711	.007	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZRANB1–BLCA (DFS)

Open the BLCA breakdown →